Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein by Tellinghuisen, Timothy L. et al.
Regulation of Hepatitis C Virion Production via
Phosphorylation of the NS5A Protein
Timothy L. Tellinghuisen*, Katie L. Foss, Jason Treadaway
The Scripps Research Institute, Scripps Florida, Jupiter, Florida, United States of America
Abstract
Hepatitis C virus (HCV) is a significant pathogen, infecting some 170 million people worldwide. Persistent virus infection
often leads to cirrhosis and liver cancer. In the infected cell many RNA directed processes must occur to maintain and
spread infection. Viral genomic RNA is constantly replicating, serving as template for translation, and being packaged into
new virus particles; processes that cannot occur simultaneously. Little is known about the regulation of these events. The
viral NS5A phosphoprotein has been proposed as a regulator of events in the HCV life cycle for years, but the details have
remained enigmatic. NS5A is a three-domain protein and the requirement of domains I and II for RNA replication is well
documented. NS5A domain III is not required for RNA replication, and the function of this region in the HCV lifecycle is
unknown. We have identified a small deletion in domain III that disrupts the production of infectious virus particles without
altering the efficiency of HCV RNA replication. This deletion disrupts virus production at an early stage of assembly, as no
intracellular virus is generated and no viral RNA and nucleocapsid protein are released from cells. Genetic mapping has
indicated a single serine residue within the deletion is responsible for the observed phenotype. This serine residue lies
within a casein kinase II consensus motif, and mutations that mimic phosphorylation suggest that phosphorylation at this
position regulates the production of infectious virus. We have shown by genetic silencing and chemical inhibition
experiments that NS5A requires casein kinase II phosphorylation at this position for virion production. A mutation that
mimics phosphorylation at this position is insensitive to these manipulations of casein kinase II activity. These data provide
the first evidence for a function of the domain III of NS5A and implicate NS5A as an important regulator of the RNA
replication and virion assembly of HCV. The ability to uncouple virus production from RNA replication, as described herein,
may be useful in understanding HCV assembly and may be therapeutically important.
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Introduction
Hepatitis C virus (HCV) chronically infects nearly 3% of the
population of the planet [1]. Persistent virus replication in these
individuals often progresses to chronic liver disease, including
cirrhosis and hepatocellular carcinoma. Since the discovery of
HCV as the causative agent of non-A, non-B hepatitis in 1989 [2],
considerable progress has been made in therapeutics, but current
anti-virals are still ineffective for the majority of patients. One of
the major obstacles to developing new anti-viral strategies is the
nebulous nature of many aspects of the HCV lifecycle. One
particularly vague area of HCV biology is that of the regulation of
the transit of RNAs from active replication to virion biogenesis.
HCV is a member of the Flaviviridae family of enveloped, single
strand positive sense RNA viruses [3]. The 9.6 kb viral genome
contains a single open reading frame encoding a polyprotein that
is cleaved co- and post-translationally to yield ten viral proteins
[4,5]. These include the structural proteins (Core, E1 and E2) and
the non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A,
and NS5B). HCV RNA replication occurs in association with ER-
like cellular membranes and requires several viral non-structural
(NS) proteins including; NS3, NS4A, NS4B, NS5A, and NS5B, as
well as host cell factors [6]. The site of virion assembly is unknown,
but recent data has proposed the recruitment of HCV RNA and
non-structural proteins by the HCV core protein from the
replicase to lipid droplets as an early event in virion assembly
[7]. Viral genomes that lack core, or contain mutations in NS5A
domain I that block lipid droplet binding, prevent the production
of infectious virions [7]. The regulatory events that control these
events are not known, but it is clear that productive virus assembly
requires the NS5A protein. The complexity of intracellular events
associated with HCV infection is staggering, with RNA involved in
active RNA replication on positive and negative strand templates,
serving as message for translation of viral proteins, and serving as a
substrate for progeny virus assembly. These events presumably
take place in functionally, and perhaps physically, distinct sub-
cellular compartments and require different viral and host factors.
There is little information of what regulates these processes to
avoid functional conflicts, but the HCV NS5A protein is an
attractive candidate for at least some of these roles.
NS5A is an absolutely required phosphoprotein component of
the replicase, but little is known about its function. NS5A is a zinc
metalloprotein organized into three discreet domains (Figure 1A)
[8]. The crystal structure of domain I suggests the functional form
of NS5A is a dimer, with a large putative RNA binding groove
located at the interface of the monomers [9]. The interaction of
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protein in RNA replication [10]. The region of NS5A required for
association with lipid droplets, a prerequisite of virion production,
is located in domain I [7]. No structural information has yet been
obtained for domains II or III. These regions are genetically
variable among HCV isolates and can tolerate insertions and
deletions without disrupting RNA replication [11–15]. Recent
genetic mapping has shown many residues in domain II are
essential for RNA replication, but domain III is dispensable [15].
Despite having no role in RNA replication, regions of sequence
conservation exist in domain III, suggesting a function in the HCV
lifecycle. NS5A localizes to the site of RNA synthesis via an N-
terminal amphipathic a-helix membrane anchor [16–18]. NS5A,
unlike the other NS proteins, can be trans-complemented,
suggesting it may have functions outside of the viral replicase
[19]. The interaction of NS5A with numerous host-signaling
pathways has been described, suggesting this protein may modify
the host cell environment to a state favorable for the virus, events
that may require an extra-replicase form of NS5A [20]. In recent
years, the phosphorylation of NS5A has become a major focus
area, as this modification may modulate the activity of NS5A in
viral and cellular processes.
NS5A is phosphorylated on multiple serine and threonine
residues and exists in hypophosphorylated (56 kDa) and hyper-
phosphorylated (58 kDa) forms [21]. The identification of which
of the many potential phosphoacceptor sites in NS5A are relevant
to these forms is not known. Nonetheless, evidence has
accumulated suggesting that hypophosphorylation primarily
targets residues in domains II and III, whereas hyperphosphoryla-
tion sites tend to cluster in and around domain I (reviewed in [22].
Cell culture adaptive mutations that increase RNA replication
tend to decrease hyperphosphorylation, suggesting NS5A phos-
phorylation may regulate replication [23]. Compounds selected to
decrease the hyperphosphorylation of NS5A increase RNA
replication, and these compounds have been shown to function
as potent and specific casein kinase 1a (CKIa) inhibitors [24].
CKIa requires pre-phosphorylation of residues near sites of
phosphorylation in NS5A for productive modification, suggesting
that other kinases also play a role in NS5A phosphorylation [25].
This effect on replication may be due to the differential association
of phosphoforms with the host hVAP-A protein, an essential
replicase component [26,27].
A host of other kinases have been shown to target NS5A in
heterologous expression/screening systems, including AKT,
p70s6K, MEK, MKK1, and CKII [22]. Perhaps the best-
characterized NS5A kinase activity, after that of CKIa, is casein
kinase II (CKII), with a number of biochemical experiments
implicating casein kinase II (CKII) as an NS5A directed kinase
[28–30]. In vitro phosphorylation of purified NS5A by CKII
incorporates 5 moles of phosphate per mole of protein, suggesting
at least five sites exist in NS5A [29]. Low-resolution mapping
studies have implicated residues in domain III as the predominant
sites of CKII phosphorylation (Kim et al., 1999). Further
experiments have indicated CKII is likely involved in basal
phosphorylation of NS5A, as hyperphosphorylated NS5A is not
produced by CKII treatment in vitro [25]. The mutation of a
number of potential CKII acceptors does not alter RNA
replication [11]. Nonetheless, a body of evidence exists implicating
CKII as an NS5A directed kinase. Recent advances in HCV
biology have allowed the complete recapitulation of the virus
lifecycle in cell culture, allowing the assessment of the function of
NS5A phosphorylation in virion production [31–34].
In this study we identify a deletion within domain III of NS5A
that disrupts the production of infectious HCV virions without
altering the replication of HCV RNA. Mapping studies suggest
that a single serine residue in a consensus CKII phosphorylation
motif is important for the observed phenotype, and phosphomi-
metic mutants at this position suggest this residue represents a
phosphorylation dependent switch controlling virion production.
CKII chemical inhibition and siRNA silencing impair infectious
virus release for viruses with a serine residue at this position,
whereas those with the aspartic acid substitution are insensitive to
these treatments. Furthermore, the over expression of CKII
increases virus production for serine but not aspartic acid bearing
viruses. These results implicate NS5A as a CKII phosphorylation
dependent regulator of particle assembly.
Results
Deletions in the NS5A protein impair the production of
infectious virions
Our previous mapping experiments in the context of the
subgenomic replicon system, and the work of others, suggested
that domain III of NS5A was not required for RNA replication
[11–15]. We hypothesized that this region might have a function
in virus particle production, at the level of RNA release from the
replicase for virion production. This hypothesis is supported, at
least in part, by the recent demonstration that the localization of
NS5A to lipid droplets is an essential prerequisite for virion
production [7]. We generated a panel of deletions within the
domain III region of NS5A of the cell culture infectious genotype
2a J6/JFH-1 virus clone to assess the importance of domain III in
virion production, including deletion A (amino acids 432–442) and
deletion B (amino acids 443–457) (Figure 1A). The preliminary
analysis of these two deletions in RNA replication and infectious
virus production by an immunohistochemical (IHC) assay is shown
in Figure 1B. In this assay in vitro transcripts of various HCV
genomic RNAs are generated and electroporated into the highly
permissive human hepatoma cell line, Huh-7.5 [35]. Following a
48 hour incubation, the supernatants are harvested, filtered, and
used to infect naı ¨ve cells. Following an additional 48 hours, cells
are fixed and IHC staining for the presence of the NS5A is
performed. Wild type virus (Figure 1B, J6/JFH-1), is capable of
replication and production of infectious virus, as evident by the
Author Summary
Hepatitis C virus (HCV) is a life-threatening infection
afflicting some 170 million people worldwide, and current
antiviral therapies are only marginally effective in treating
these patients. Clearly, more effective anti-viral drugs for
HCV are needed. Of paramount importance to this process
is understanding the detailed mechanisms HCV uses to
infect cells, replicate the viral genome, assemble progeny
virus, and exit the cell. Using genetic mapping, we have
identified a single amino acid residue of the HCV NS5A
protein that is phosphorylated by host cell kinase, and this
modification regulates the production of new infectious
virus particles. This modification of NS5A results in the
release of some of the viral genome from replicative
events, thereby making this material available for progeny
virus particle production. We have identified genetic and
chemical methods to modulate this event, resulting in our
ability to control the production of infectious virus
particles in the laboratory. The ability to separate the
replication of the virus genetic material and the assembly
of new viruses allows us a valuable tool to monitor how
this process occurs and, potentially, a novel target for the
development of much needed anti-viral drugs.
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PLoS Pathogens | www.plospathogens.org 2 2008 | Volume 4 | Issue 3 | e1000032Figure 1. A Deletion in NS5A Domain III Disrupts the Production of Infectious Virus. A). Schematic representation of the domain
organization of NS5A indicating the locations of the three domains and low complexity domain connectors (LCS). The location of the membrane
anchoring helix is also shown. Numbers indicate amino acid positions on the Con1 genotype 1b NS5A sequence. Sequences of the C terminus of
NS5A indicated by the black box on the schematic are shown below for representative sequences of major HCV genotypes. The sequences shown are
1a H77 (AF011753), 1b Con1 (AJ238799), 2a JFH-1 (AB047639), 2b HC-J8 (D10988), 3a HCVCEN (X76918), 4a ED43 (Y11604), 5a EUH1480 (Y13184), and
6a 6a33 (AY859526). B). IHC analysis of cells electroporated with indicated viral RNAs (top of image rows) for NS5A 48 hours post electroporation (top
row of panels) or 48 hours post infection (bottom row of panels). C). Western blot of wild type (WT) and deletion B (del B) NS5A from cells
electroporated with replication competent full-length genomes shown in B and D. D). RNA replication 48 hour time course of J6/JFH-1 (blue line), J6/
JFH-1 deletion B (red line), or J6/JFH-1 pol- (black line) as determined by real time PCR analysis. E). RNA replication 48 hour time course of indicated
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infected cells. A viral RNA with a lethal lesion in the HCV RNA
polymerase (J6/JFH-1 pol-) coding sequence is incapable of
replication and infection. Deletion A generated results very similar
to the wild type virus, with replication and infection occurring at
levels comparable between these two constructs. Deletion B,
although showing RNA replication levels similar to that seen for
the wild type J6/JFH-1 construct, did not generate any detectable
infectious virus production (Figure 1B, last column of images),
indicating deletion B could disrupt infectious virus production,
while not altering RNA replication.
A more quantitative approach than NS5A IHC was used to
better characterize the deletion B virus. For these experiments,
HCV RNA transcripts corresponding to wild type J6/JFH-1, J6/
JFH-1 pol-, and J6/JFH-1 deletion B were generated and
electroporated into Huh-7.5 cells. The cells were plated and
following a four hour recovery time, total cellular RNA was
harvested in a time course experiment spanning 48 hours. HCV
RNA was detected in these samples by quantitative real-time
reverse transcription PCR using HCV specific probes and primers.
Human GAPDH mRNA was also measured for purposes of data
normalization. Figure 1C shows the RNA replication kinetics for
J6/JFH-1 and J6/JFH-1 deletion B are identical, indicating
deletion B does not affect HCV RNA replication. As lateral spread
of virus infection in the J6/JFH-1 electroporated cells, and not in
the J6/JFH-1 deletion B cells, could possibly skew results in this
type of experiment, we further analyzed the effect of deletion B on
RNA replication in the context of the non-infectious HCV 2a
replicon, pSGR-JFH-1. Figure 1D shows that RNA replication
was not altered for deletion B bearing RNAs in the context of non-
infectious HCV replicons. From these data it is clear than deletion
B does not alter HCV RNA replication. Turning to the production
of infectious virus, we electroporated J6/JFH-1, J6/JFH-1 pol-,
and J6/JFH-1 deletion B RNAs into cells, harvested supernatants
after 48 hours, and titered the infectious virus in these superna-
tants by a limiting dilution assay. Viral titers are shown in Figure 1
E in units of 50% tissue culture infectious units per milliliter
(TCID50/ml). J6/JFH-1 yielded a TCID50/ml titer of 5.5610
5
and the lethal pol- lesion prevented production of infectious
particles. J6/JFH-1 deletion B, despite having RNA replication
levels indistinguishable from J6/JFH-1, failed to produce any
detectable infectious virus in this assay. To determine if deletion B
simply delayed the kinetics of virus production, we incubated
electroporated cells for six days post RNA delivery and titered the
output of infectious virus from these cultures. We saw no infectious
virus production from cells electroporated with deletion B RNA
from these six day cultures (Figure 1E), indicating deletion B did
not simply induce a kinetic delay in virion production. Further-
more, we have kept deletion B RNA in the context of a neomycin
selectable, bicistronic full-length viral genome (FLneo J6/JFH-1,
as described in [31] for more than 5 months with no detectable
infectious virus output from these cultures (data not shown).
Only a small fraction of the total HCV non-structural proteins
present within a cell are actively involved in the process of viral
RNA replication [36]. One can easily imagine a mutant that
destabilizes NS5A sufficiently so as to eliminate the non-replicative
form of the protein, yet retaining enough trace NS5A protein to
allow for productive RNA replication. If the non-replicative excess
of non-structural proteins are somehow involved in particle
assembly, a simple defect in protein stability could lead to a
phenotype similar to what we observe with deletion B. To
investigate this possibility we performed Western blots to assay the
level of NS5A expression in cells electroporated with replication
competent wild-type and deletion B full-length viral genomes.
Figure 1C shows the results of this analysis. No obvious defect in
the levels of NS5A were apparent, but, interestingly, the
phosphoform distribution was altered. Wild-type NS5A was
present as an even mixture of hyper- and hypophosphorylated
forms, whereas deletion B was present in predominantly the
hypophosphorylated form, with a small but detectable amount of
hyperphosphorylated protein. This observation, combined with
the removal of a number of serine residues in the deletion B NS5A
protein relative to the wild type sequence suggested that our
mutation disrupted one or more phosphorylation sites.
The lack of detectable infectious virus observed for the J6/JFH-
1 deletion B construct raised the question as to where in the HCV
life cycle the defect in infectivity release might be located. HCV,
by analogy to related viruses, most likely buds virions into the ER
or an ER-like compartment, and virions are exported from the cell
using the host secretory machinery. It has been shown that
significant amounts of infectious HCV virions are present inside
the infected cell, and can be liberated by simple repetitive freeze-
thaw lysis of the cell [37]. To determine if J6/JFH-1 deletion B
generates infectious particles that fail to exit the cell, we performed
electroporations of this RNA and the parental J6/JFH-1 RNA,
incubated the cells for 48 hours, and lysed the cells by freeze thaw
after extensive pre-lysis washing to remove virus released by
normal exocytosis. Cell lysates were then titered by limiting
dilution on naı ¨ve Huh-7.5 cells. J6/JFH-1 pol-, as expected,
produced no infectious virus in these experiments (Figure 1F). J6/
JFH1 liberated approximately 10
4 infectious units after freeze
thaw. Deletion B failed to release any infectious virus in this
experiment, suggesting the defect observed for deletion B was not
at the step of virus release from the cell, but at an earlier step in
virion biogenesis. We next monitored HCV RNA release into the
supernatant of infected cells to determine if these cells release
RNA and/or HCV particles that are somehow defective in
initiation of infection. Figure 1G presents the results of this
analysis, with HCV RNA present in cell supernatants quantified
by real-time reverse transcriptase PCR using HCV specific
primers and probe and presented as relative RNA release to the
level of RNA released by a J6/JFH-1 pol- RNA. As expected, wild
type J6/JFH-1 infected cells release RNA into the cell culture
supernatant, consistent with the release of packaged infectious
particles. Deletion B bearing J6/JFH-1 released approximately 525
fold less RNA than wild type J6/JFH-1. RNA release for J6/JFH-1
deletion B was comparable to the non-infectious H77/JFH-1
chimeric virus construct [31] and less than that observed for a
subgenomic RNA, pSGR-JFH-1 [38]. These data suggest that the
J6/JFH-1 deletion B either does not assemble virions at all or it may
release non-infectious particles lacking the HCV genome. To
address these possibilities we next looked at HCV core protein, a
component of the HCV virion, in the supernatants of J6/JFH-1 and
J6/JFH-1 deletion B electroporated cells using the commercially
subgenomic replicon RNAs. pSGR-JFH-1 (red line), pSGR-JFH-1 deletion B (blue line), and pSGR-JFH-1 pol- (black line). F). Infectivity release 48 hours
(gray bars) and 6 days post (black bars) electroporation from indicated viral RNA electroporated cells in units of tissue culture infectious dose 50%
value per milliliter. G). Infectivity released from cells via freeze-thaw treatment 48 hours post electroporation from indicated viral RNA electroporated
cells. H). Relative HCV RNA release from cells electroporated with the indicated HCV constructs. Values reported are arbitrary units normalized to the
RNA release by a non-replicating J6/JFH-1 pol-.
doi:10.1371/journal.ppat.1000032.g001
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assay in HCV cell culture infection experiments as a means to
measure virion release is well documented [39,40]. Table 1
summarizes core protein released at 24 hours post RNA electro-
poration. J6/JFH-1 pol- RNA electroporated cells released
21.33 femptomoles/L of core protein, establishing the baseline for
a non-replicating viral genome. J6/JFH-1 electroporated cells, in
contrast, released 2225 femptomoles/L of HCV core, indicating a
robust release of core protein. The J6/JFH-1 deletion B
electroporated cells released 58 femptomoles/L, considerably less
core than the parental J6/JFH-1 electroporated cells. Cell lysates of
J6/JFH-1 and J6/JFH-1 deletion B contained comparable amounts
of core protein when analyzed by this ELISA assay, indicating no
defect in core protein production existed (data not shown).
Collectively, these data suggest the defect in J6/JFH-1 deletion B
is at an early step of virion production. No viral RNA, capsid
protein, or infectious virus are released from cells replicating
deletion B RNA, and infectious virions are not merely trapped
within the secretory pathway for this mutant.
Identification of Serine 457 of NS5A as a key determinant
for virus production
As the preliminary characterization of J6/JFH-1deletion B
suggested this region of NS5A was important for the production of
infectious HCV virions, we decided to map what residues in
deletion B were responsible for this phenotype. We therefore
generated three smaller deletions, designated B1 (amino acids
443–447), deletion B-2 (amino acids 448–452) and deletion B-3
(amino acids 453–457), in the context of the wild type J6/JFH-1
virus (Figure 2A). Each of these deletions was capable of robust
HCV RNA replication (Figure 2B, top row of images). Deletions
B-1, B-2, and B-3 were also capable of producing infectious virus,
although deletion B-3 produced considerably less infectious virus
than deletion B-1 and B-2 (Figure 2B, bottom row of images).
However, none of these deletions was capable of reproducing the
complete loss of infectivity release observed with the original
deletion B mutant. From these mutants it was clear that none of
the residues in deletion B-1 or B2 were essential for virus
production. Residues in deletion B-3 clearly have some impact of
infectivity release, but not to the extent of deletion B. As deletions
B-1, B-2, and B-3 completely span the parental deletion B region,
we were puzzled by our inability to map the region of deletion B
involved in the disruption of infectivity release. Upon closer
examination of the deletions we generated we noticed that
generating deletion B-3 positioned an upstream serine residue at
position 452 (residue highlighted in red in Figure 2A) in a position
analogous to serine 457 that was removed in deletion B-3. This
data hinted that having a serine in this position might be
important for the production of infectious virus, and also suggested
that residues upstream from that serine (deletion B-3 region) might
have some impact of infectivity release, as evidenced by deletion B-
3’s reduced infectivity release. We therefore generated two
additional deletions, deletion B-4 (amino acids 457–460, sequence
SEED) and deletion B-5 (amino acids 458–460, sequence EED), to
evaluate the importance residues near this serine (Figure 2C). Both
deletions B-4 and B-5 were capable of efficient replication upon
electroporation of these RNAs into cells (Figure 2D). Deletion B-4,
removing serine 457 and three downstream residues, failed to
generate infectious virus in a manner similar to that observed for
the parental deletion B (Figure 1B). Deletion B-4, retaining serine
457 and deleting only the three downstream residues, produced a
robust level of infectivity. Collectively, these studies implicate
serine 457 as a key residue in the production of infection virus,
although the involvement of other residues in this region
(specifically in deletion B-3) may affect the efficiency of this
process. We have subsequently generated deletions of serine 457
alone, and this also blocks infectivity release (data not shown). We
next analyzed the stability and phosphorylation state of our NS5A
deletions by Western blotting lysates prepared from cells
electroporated with the constructs shown in Figure 2, panel B
and D. Figure 2, panels E and F show the results of this analysis.
No obvious defects in NS5A stability were evident for any of the
mutant NS5A proteins. Interestingly, we observed less hyperpho-
sphorylated NS5A with deletion B-3 and B-4, deletions which
reduced infectivity release. This is reminiscent of our observations
with the parental deletion B, again suggesting these mutations alter
hyperphosphorylation of NS5A.
Mutations suggest the phosphorylation of Serine 457
regulates RNA replication and infectious virus production
As our mapping studies suggested that serine 457 of NS5A was
an important residue for the production of infectious HCV, and
the phosphorylation of NS5A by a number of cellular kinases is
well documented in the literature, we explored the possibility that
serine 457 was a phosphoacceptor site. The web based NetPhosK
server strongly predicted serine 457 as a site of CKII phosphor-
ylation, with serine 457 present in an ideal motif for CKII
phosphorylation (SEED sequence) [41]. We proceeded with the
hypothesis that serine 457 is a phosphoacceptor site, and that this
site is a target of CKII. We therefore generated mutations at
position 457 in the context of the infectious J6/JFH-1 viral
genome, including an alanine substitution (AEED) that is
incapable of phosphorylation at position 457, an aspartic acid
(DEED) that should mimic phosphorylation at this site, and a
serine to serine codon change (SEEDcc) that should be capable of
phosphorylation and eliminate any chances that our previous
mapping work merely disrupted an RNA packaging signal or other
RNA element required for infectious virus production. Figure 3A
shows the analysis of these mutants using the IHC NS5A detection
assay for replication and infection. The substitution of alanine for
the serine at position 457 did not alter RNA replication, but
blocked the production of infectious virus and the subsequent
infection of naı ¨ve cells, although a few infected cells were visible in
this experiment. The aspartic acid mutation (DEED) and the
serine codon change mutation (SEEDcc) had not obvious effect on
RNA replication or infectivity release in this assay. Using the more
quantitative real-time PCR based assay, we generated transient
RNA replication curves for all of our mutations at position 457
and the wild type and deletion B bearing J6/JFH-1 RNAs
(Figure 3B). J6/JFH-1, J6/JFH-1 deletion B, J6/JFH-1 AEED,
and J6/JFH-1 SEEDcc RNAs had no measurable defect in RNA
accumulation levels or the kinetics of RNA accumulation. The J6/
JFH-1 DEED mutant showed a small but reproducible K log
reduction in RNA levels in this assay. We next looked at the
Table 1. Core protein release.
Sample
a Core Released (fmoles / L)
a
J6/JFH-1 pol- 21.33 (+/22.52)
J6/JFH-1 2225 (+/228.48)
J6/JFH-1 deletion B 58 (+/23.61)
aValues reported as average of three independent experiments in the format
‘‘average value (+/2standard deviation)’’ in units of femptomoles of HCV core
protein per liter 24 hours post electroporation.
doi:10.1371/journal.ppat.1000032.t001
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released virus in the supernatants by limiting dilution (Figure 3C).
J6/JFH-1 released approximately 5.5610
5 TCID50/ml, with the
lethal polymerase lesion (J6/JFH-1 pol-) releasing no infectious
virions. J6/JFH-1 deletion B, as shown in previous experiments,
failed to release any detectable infectivity. The J6/JFH-1 AEED
mutant virus released infectious virus at very low levels (about 60–
80 TCID50/ml), in good agreement with the observation of a few
NS5A positive cells in the lower infection panel in Figure 3A,
indicating that substitution of serine 457 to alanine inhibited
infectivity release by about five orders of magnitude. The low level
of infectivity release suggested these infected cells might be
harboring revertants. We expanded these serine 457 to alanine
infected cultures, extracted RNA, and performed RT-PCR based
sequencing on the bulk population. This analysis revealed that the
input alanine mutation was retained in the infectious virus
produced by this mutant, indicating the requirement of serine
457 may not be absolute, or that other changes elsewhere in the
Figure 2. Mapping the disruption of infectious virus production. A). Sequence of JFH-1 NS5A around the region of deletion B (indicated by
gray line). Deletions B-1, B-2 and B-3 are indicated by black bars. Numbers refer to amino acid numbering of the mature JFH-1 NS5A protein. Residue
serine 452 is shown in red. B). IHC analysis of cells electroporated with indicated deletion bearing viral RNAs (top of image rows) for NS5A 48 hours
post electroporation (top row of panels) or 48 hours post infection (bottom row of panels). Numbers beneath each panel are HCV RNA copies per
100 ng of total RNA (top row of images) and infectivity release from titering (bottom row of images). C). Sequence of JFH-1, as described in A, now
showing the location of deletion B-4 and B-5 with black bars. D). IHC analysis of deletion B-4 and B-5. Panel layout is as described in B. Numbers
below the images are as described in B. E). Western blot analysis of NS5A from cells electroporated with replication competent full-length viral
genomes of wild-type (WT) and deletions B-1, B-2, and B-3 (del B1, del B2, and del B3) shown in panel B. F). Western blot analysis of NS5A from cells
electroporated with replication competent full-length viral genomes as shown in panel D. Nomenclature is as described in E.
doi:10.1371/journal.ppat.1000032.g002
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We sequenced the entire HCV coding sequence and were unable
to identify any additional sequence changes, furthering the idea
that a low level of particle production may occur even in the
absence of serine 457. The J6/JFH-1 DEED released virus at
about 3610
5 TCID50/ml, indicating aspartic acid was an
acceptable substitution at position 457. J6/JFH-1 SEEDcc
produced a virus titer similar to that of wild type J6/JFH-1,
indicating changes in the HCV RNA sequence at this position
were not responsible for the observed reduction in infectious virus
production. Analysis of the stability and phosphorylation state of
these mutants (Figure 3D) revealed no obvious defect in stability
and a loss of some hyperphosphorylated NS5A in the AEED
mutant. The reduction of NS5A hyperphosphorylation seems to be
common to all of our mutants that are of reduced infectivity release.
At first glance it would seem likely that serine 457 is a
phosphoacceptor site, and the alteration or deletion of this residue
leads to reduced levels of hyperphosphorylated NS5A. However,
the situation is more complex, as the DEED mutant also eliminates
this serine residue, yet has levels of hyperphosphorylation
comparable to wild type NS5A or the many virus release competent
mutations. The data suggests that serine 457 phosphorylation is a
prerequisite to modification of other phosphoacceptors involved in
generating hyperphosphorylated NS5A.
Figure 3. Single amino acid mutations that mimic phosphorylation of serine 457 alter particle assembly. A). IHC analysis of cells
electroporated with indicated point mutation bearing viral RNAs. AEED indicates mutation of serine 457 to alanine, DEED is the same residue
changed to aspartic acid, SEEDcc is a change of the codon of serine 457 while retaining serine at this position. Rows of images are as described in 1B,
2B and 2D. B). RNA replication 48 hour time course of J6/JFH-1 (red line), J6/JFH-1 deletion B (blue line), J6/JFH-1 pol- (black line), AEED RNA (green
line), DEED RNA (purple line), and SEEDcc RNA (light blue line) as determined by real time PCR analysis. C). Infectivity release 48 hours post
electroporation from indicated viral RNA electroporated cells in units of tissue culture infectious dose 50% value per milliliter. D). Western blot
analysis of NS5A from cells electroporated with replication competent full-length viral genomes as shown in panel A. Nomenclature used is as
described in A.
doi:10.1371/journal.ppat.1000032.g003
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production
To determine if CKII phosphorylation of serine 457 was
important for the process of virion biogenesis in vivo we
investigated the use of the specific CKII inhibitor 2-dimethyla-
mino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) on infec-
tious virus release. DMAT is a cell-permeable ATP-competitive
inhibitor that displays a 1,300 fold selectivity for CKII over CKI
and has been shown to minimally affect a large number of other
protein kinase activities [42]. Huh-7.5 cells were electroporated
with transcripts of the infectious J6/JFH-1 RNA and DMAT was
added to cell culture media four hours after RNA delivery.
Following three days of further incubation, supernatants of these
cultures were collected and used to infect naı ¨ve Huh-7.5 cells.
Figure 4A shows IHC staining of the NS5A protein in these
infected cells for two doses (0.5 mM and 2 mM) of DMAT and a
DMSO only vehicle control. Robust infections of naı ¨ve cells is
evident with the transfer of supernatants from the DMSO only
treated cells, and a dose dependent reduction in infectious virion
content is seen in infections using supernatants from DMAT
treated cells. A more quantitative analysis of the effects of DMAT
treatment on infectious virus production is presented in Figure 4B.
For this experiment, cells were electroporated with J6/JFH-1
RNA transcripts, plated and incubated for four hours, and doses of
DMAT were added to the cells. Following three days of
incubation, cell supernatants were harvested for tittering on naı ¨ve
cells. As observed in Figure 1A, a dose dependent inhibition of
infectious virus release was observed with DMAT treatment, with
no effect observed for DMSO vehicle only treatment. Infectious
virus titers were plotted as the percent of infectivity release relative
to the DMSO only treated cells versus the dose of DMAT. The
EC50 (effective concentration 50%) of DMAT inhibition of
infectivity release was calculated at 180 nM, in good agreement
with the published IC50 (inhibitory concentration 50%) of DMAT
of 140 nM as assayed on purified rat liver CKII [42]. Although
these data suggested CKII activity was important for the
production of infectious virions, it did not provide information
about the phosphorylation of serine 457 of NS5A in this process.
We therefore assayed the aspartic acid mutation at position 457 of
NS5A in these experiments, based on the concept that aspartic
acid should mimic phosphorylation of position 457 and make
NS5A insensitive to CKII, and therefore, DMAT inhibition. The
aspartic acid mutation at position 457 (Figure 4B, DEED) was
insensitive to DMAT inhibition of infectivity release, with an EC50
value (5.5 mM, Figure 4B red line) close to the LD50 (lethal dose
50%) of DMAT on Huh-7.5 cells (6.5 mM, Figure 4B dashed line),
suggesting that the inhibition of infectivity release for the aspartic
acid mutation was largely due to cytotoxic effects of drug
treatment. The roughly 30-fold difference in EC50 values of
DMAT on wild type NS5A versus the aspartic acid mutation
implicates serine 457 phosphorylation as an important event in
infectious virus production and suggests that other possible CKII
sites in NS5A have little role in this process. The replication of wild
type or DEED HCV RNA, as determined by monitoring levels of
genomic RNA in cells by real-time PCR, was not affected by
treatment with DMAT up to the level where DMAT toxicity was
observed (Figure 4C). Treatment of cells with an unrelated
nucleotide analog kinase inhibitor, 2-aminopurine, had no effect
on infectious virus release when used either to treat cells prior to
infection or when maintained during the entire course of the
experiment (figure 4D). As the NS2 protein is known to be a key
determinant in the production of infectious virus, and also
documented to contain a CKII site that can regulate the stability
of NS2 [43], we treated cells infected with the JC1 HCV virus [44]
with the DMAT inhibitor and monitored the stability of NS2 over
the course of our previous measurements of infectivity (Figure 4E).
The use of the JC1 virus, which alters the location of the junction
between J6 and JFH-1 genomes in the region of NS2 was
necessary, as we only have antibodies that recognize the JC1 form
of NS2, and not that present in J6/JFH-1. In any case, the putative
CKII site in NS2 is not different in these different viral constructs.
We observed no difference in NS2 stability from 0.125 to 2 mM
DMAT, a slight reduction in NS2 levels at 4 mM, and a nearly
complete loss of NS2 at 6 mM. These data, combined with our
observed EC50 for DMAT on infectious virus production for wild
type NS5A bearing virus (180 nM), suggest that alterations in NS2
levels are not a significant factor in our experiments.
Silencing casein kinase II expression disrupts virus
production
Although the chemical inhibition of infectious virion production
by the specific CKII inhibitor DMAT suggested CKII phosphor-
ylates NS5A, the possibility existed that other kinases were
inhibited by DMAT and were responsible for infectious virus
production. To address this point we chose to specifically silence
CKII gene expression. CKII exists as a tetramer composed of 2 b
regulatory subunits and two a kinase subunits [45]. Two isoforms
of CKII a subunits exist, designated a and a9. These a/a9 isoforms
can assemble with 2 b subunits in a homotypic (all a or all a9
subunits in the CKII holoenzyme) or heterotypic manner (a and
a9 in the CKII holoenzyme). As it was unclear which subunit
might be involved in NS5A phosphorylation, we chose to silence
both a and a9 expression individually as well as a9 and a
simultaneously. siRNAs (CKII a, a9, a mix of a and a9,o ra n
irrelevant siRNA) were delivered to cells via electroporation and
the cells were plated and incubated for 24, 48 and 72 hours prior
to harvesting protein lysates and total cellular RNA to determine
the efficacy of silencing. Figure 5A shows Western blotting of cells
treated with the various siRNAs using CKII a and a9 specific anti-
sera. In all samples, a decrease in the amount of the targeting
CKII alpha subunit(s) was evident within 24 hours, with little or
no CKII a or a9detectable by 72 hours. To further confirm our
silencing of the CKII kinase subunits we performed real-time
reverse transcription PCR using primers and probes targeting
CKII a and a9 mRNA (Figure 5C). We were able to reduce CKII
a mRNA levels by about 60% relative to the level of an untreated
control, and CKII a9 by approximately 65%. Cells treated with
both CKII a and a9 RNAs (Figure 5C, Mix) showed similar
silencing to cells treated with a single siRNA, although silencing
was somewhat more efficient in cells receiving the mixture of both
CKII siRNAs. Measurement of cell viability at 72 hours indicated
that our siRNA treatments had little negative affect on the cells,
with all cells at least 95% or better than the viability of untreated
cells (Figure 5B). We therefore chose to conduct all future
experiments 72 hours post siRNA delivery. Following siRNA
electroporation and a 72 hour incubation, cells were infected with
J6/JFH-1 or DEED virus at a multiplicity of infection of five. After
five hours, the virus inoculum was removed and the cells washed
extensively. After 48 hours of infection, supernatants were
harvested and titered for the presence of infectious virus. J6/
JFH-1 virus production was inhibited by silencing of either CKII a
or a9, with reductions in virus yield of about 80% relative to an
irrelevant siRNA control (Figure 5D). Silencing of CKII a and a9
together impaired wild type virus production by more that 98%. It
should be noted that although silencing of CKII a or a9
individually did not significantly alter HCV RNA replication in
these experiments, but silencing both CKII a and a9 together led
to a one log reduction in HCV RNA levels (Figure 5D). This lower
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PLoS Pathogens | www.plospathogens.org 8 2008 | Volume 4 | Issue 3 | e1000032Figure 4. The casein kinase II inhibitor DMAT disrupts the production of infectious virus. A). IHC infectivity assay showing cells 48 hours
post infection stained for NS5A expression. Individual images correspond to cells treated with DMSO, 0.5 mM DMAT in DMSO, and 2 mM DMAT
4 hours after electroporation. B). Infectivity release of J6/JFH-1 and J6/JFH-1 DEED 48 hours post electroporation versus dose of DMAT added to cells.
Values shown are percent infectivity release of DMSO treated cells receiving identical viral RNAs. Cell viability is percent viable cells of a DMSO only
treated control cells as measured by an ATP based cell viability assay. C). HCV RNA replication 48 hours post indicated concentration of DMAT
treatment for J6/JFH-1 (light gray bars) and J6/JFH-1 DEED (dark gray bars) RNA electroporations. Bars designated zero are DMSO only treated. D).
Treatment of cells with an unrelated kinase inhibitor, 2-aminopurine (2-AP), does not affect infectious virus release. Cells were treated with 2-AP at the
indicated concentration or a DMSO control for 1 hour prior to infection. Virus output was then titered 48 hours post infection. In another experiment,
2-AP, was left in the culture medium at 1 mM for the 48 hour course of the experiment (black bars). E). Effect of CKII inhibition with DMAT on NS2
stability. Indicated doses of DMAT were added to cells electroporated with JC1 HCV RNA for a period of 48 hours. Following this treatment, cells were
lysed and Western blots for NS2 (top row) and b-actin (bottom row) were performed to look for differences in NS2 stability.
doi:10.1371/journal.ppat.1000032.g004
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virus inhibition in samples where both CKII a and a9 were
silenced. The DEED mutation bearing virus infected cells were
not inhibited in virus release when CKII a or a9 were silenced
individually or in combination, in contrast to what was observed in
J6/JFH-1 wild-type infections (Figure 5E). The DEED infections
also had about a one log drop in HCV RNA in cells in which
CKII a and a9 were both silenced (Figure 5D), but this did not
alter virus production for these cells (Figure 5E). This, perhaps, not
surprising as virus constructs such as JC1 are capable of increasing
infectivity release without altering the levels of RNA replication,
suggesting the relationship between replicating RNA and virion
packaged RNA is not stoichiometric [44]. The siRNA data overall
is similar to our use of the CKII inhibitor, DMAT, and collectively
these experiments highlight the importance of serine 457
phosphorylation by CKII in the production of infectious virus.
Over expression of CKII alpha increases virus production
Although chemical and genetic inhibition of CKII activity has
suggested the importance of this kinase in the production of
infectious virus for HCV, it remains a possibility that these
treatments altered some other aspect of the host cell physiology.
We therefore chose to over express the a and a9 subunits of CKII
from a CMV promoter based plasmid and assay the effects of this
on infectious virus release. The expression of CKII a has been
shown to increase the production of the regulatory b subunit in
cells, making delivery of exogenous CKII b not necessary [46].
We transiently transfected cells with pCMVSport6 CKII a,
pCMVSport6 CKII a9, or a pCMVSport6 empty vector control,
and following a 24 hour incubation to allow for expression of
CKII a subunits, cells were infected with J6/JFH-1 virus. A
Western blot image showing the level of CKII alpha subunit
relative to a b-actin loading control are shown in Figure 5F. After
48 hours, cell culture supernatants were titered for the presence of
infectious virus on naı ¨ve Huh-7.5 cells. Table 2 presents the results
of this experiment, with values listed as fold increase in infectious
virus release relative to a non-plasmid transfected cell control. The
presence of the pCMVSport6 control vector had no affect on the
production of infectious virus, but the expression of CKII a from
this vector led to a 3.44 fold increase in infectious J6/JFH-1 virus
yield. Similarly, CKII a9 led to a 2.95 fold increase in virus titers.
We also conducted a parallel experiment in which similarly
transfected cells were infected with a J6/JFH-1 DEED mutant
virus. The DEED mutant virus showed no increase in virus
production with the over expression of CKII a (0.83 fold change)
or CKII a9 (0.94 fold change) (Table 2). These data highlight the
importance of CKII to infectious virus production, and in the case
of the DEED mutant virus, the importance of a single residue of
the NS5A protein to this process.
Serine 457 is phosphorylated by CKII in vitro
Although our genetic and chemical manipulations of NS5A
suggest serine 457 is phosphorylated by CKII, we have not shown
direct modification of this residue by this kinase. Indeed, only two
sites of NS5A phosphorylation have been mapped despite intense
efforts in this regard over the past 15 years [47,48]. This is, at least
in part, due to the large number of potential acceptor sites in
NS5A and the unusual repetitive amino acid usage of potential
acceptor sites in several regions of NS5A. Our efforts in attempting
to identify serine 457 as a phosphoacceptor from NS5A isolated
from infected cells by immunoprecipitation and mass spectrometry
have not been successful due to poor coverage of the domain III
region of NS5A in our spectra (data not shown). We therefore
decided to analyze the deletion B region as a potential CKII
substrate using in vitro kinase reactions on GST fusion protein
substrates. We generated two GST fusion proteins for use as in
vitro substrates for CKII phosphorylation. The first contained
amino acids 449 to 465 (GSGSWSTCSEEDDTTVV, in single
letter amino acid designation) from the JFH-1 NS5A protein fused
to the C-terminus of GST. The second fusion protein was identical
with the exception of the substitution of serine 457 with an alanine
residue (GSGSWSTCAEEDDTTVV). Following incubation with
recombinant human CKII in the presence of c-
33P ATP, we
captured the proteins on glutathione agarose beads and deter-
mined radiolabel incorporation by liquid scintillation counting.
This data is presented in Figure 6. Proteins were first analyzed in
the absence of added CKII to assess the level of phosphate
incorporation that might be present from co-purifying kinase
activities. All of the proteins showed similar levels of incorporation
in these reactions, indicating that the purified proteins were
essentially equivalent in regard to potential kinase contamination.
Figure 5. Levels of CKII a and a9 subunits affects infectious virus production. A). Western blots of cells electroporated with CKI a, CKIa9,o r
both CKIa and CKIa9 siRNAs are indicated and probed with antibodies recognizing CKI a, CKIa9, or both CKIa and CKIa9. A time course of 72 hours
post siRNA delivery is shown. b-actin loading control panels are shown in the lower row of images. B). Cell viability, expressed as percent viability of
cells electroporated with no siRNA, for cells electroporated with irrelevant siRNA (IRR), CKI a (CKIA), CKIa9 (CKIA9), or both CKIa and CKIa9 (MIX) as
determined by ATP activity assay. C). CKI a and CKIa9 messenger RNA levels, relative to GAPDH in arbitrary units. Dark lines and text cues indicate
which real time PCR probe set was used for each set of bars. Designations under bars indicate the siRNA delivered to the cells. Designations of siRNAs
are as described in B. D). HCV RNA replication 72 hours post siRNA treatment for cells treated with various siRNAs (labels below columns) and
infected with HCV viruses indicated below the dark bars (J6/JFH-1 or J6/JFH-1 with the DEED mutation). Column colors further highlight the different
viruses used for these experiments, with light gray for J6/JFH-1 infected samples, and dark gray for J6/JFH-1 DEED infected samples. E). Infectivity
release 72 hours post treatment with the indicated siRNAs (column labels) for cells infected with viruses indicated by dark bars (J6/JFH-1 or J6/JFH-1
with the DEED mutation). Column bar colors are as designated in D. F). CKII a and CKIIa9 catalytic subunit over-expression (OE) relative to cells
transfected with an empty vector (M). Western blots using CKII a and CKIIa9 antisera as indicated. b-actin Western blot of samples shown in over-
expression samples as a loading control.
doi:10.1371/journal.ppat.1000032.g005
Table 2. CKII over expression increases infectious virus
release.
Sample
a Fold Increase in Virus Titer
b
J6/JFH-1+vector 0
J6/JFH-1+CKIIa 3.44 (+/20.21)
J6/JFH-1+CKIIa9 2.95 (+/20.28)
J6/JFH-1 DEED+vector 0
J6/JFH-1 DEED+CKIIa 0.83 (+/20.23)
J6/JFH-1 DEED+CKIIa9 0.94 (+/20.32)
aSample column organized as ‘‘infecting virus+input expression construct’’.
bValues reported as average of three independent experiments in the format
‘‘average value (+/2standard deviation)’’ increase relative to non-transfected
control.
doi:10.1371/journal.ppat.1000032.t002
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Figure 6) incorporated about 3 times more radiolabel than GST
with no fusion in the presence of recombinant CKII, indicating
residues in the fusion sequence were modified by CKII. The fusion
protein in which serine 457 was changed to an alanine residue, but
was otherwise identical to the SEED fusion protein, did not show
this increased label incorporation relative to the GST control,
suggesting that the modification of the SEED fusion protein
involved serine 457. These data confirm that serine 457 is a valid
CKII target, at least in these in vitro reactions. We have attempted
to detect the effects of CKII a over-expression and the DMAT
inhibitor on NS5A phosphorylation in the context of an HCV cell
culture infection. Unfortunately, we observe only a very small
effect on NS5A hyperphosphorylation with CKII a over-
expression (Figure 6B), and only a very moderate decrease in
hyperphosphorylation (Figure 6C) with these treatments. These
data are far less dramatic that our previous genetic manipulations,
suggesting more advanced phosphopeptide mapping will be
required to provide a definitive answer on whether NS5A
phosphorylation is altered by these treatments.
Deletion B does not disrupt localization of NS5A to lipid
droplets
Recent research has implicated the lipid droplet as an important
organelle in the production of HCV virions [7]. The localization of
Figure 6. Serine 457 is phosphorylated by CKII in vitro and in vivo. A). Results of in vitro phosphorylation analysis of GST fusion proteins of
the region of NS5A surrounding serine 457 presented as counts per minute (c.p.m.) of c-
32P incorporation. A non fusion protein form of GST assayed
in the absence (GST only) and presence of recombinant human CKII (GST+CKII) serve as negative controls. GST fused to the NS5A derived sequence
SGSGWSTCSEEDTTVV, which corresponds to a wild type sequence surrounding serine 457, was assayed in the absence (SEED only) and presence of
CKII (SEED+CKII). GST fused to the NS5A derived sequence SGSGWSTCAEEDTTVV, which replaces serine 457 with an alanine residue but otherwise
retains a wild type NS5A sequence, was also analyzed for phosphate incorporation in the absence (AEED only) and presence (AEED+CKII) of purified
CKII. B). Results of CKII over-expression on NS5A phosphorylation during a virus infection. Cells were transfected with an empty expression vector
construct (Mock) or a construct expressing human CKII a, lysed, and lysates probed with the 9E10 anti-NS5A monoclonal antibody. C). Analysis of
DMAT treatment on NS5A phosphorylation. DMAT or vehicle (DMSO) was added to cells at a concentration of 250 nM for a period of two days. Cell
lysates were than analyzed as described for B.
doi:10.1371/journal.ppat.1000032.g006
Regulation of Hepatitis C Virus Production
PLoS Pathogens | www.plospathogens.org 12 2008 | Volume 4 | Issue 3 | e1000032HCV core to lipid droplets, and the subsequence recruitment of
viral RNA and non-structural proteins are prerequisites of virion
production. A mutation in the domain I region of NS5A that
disrupts lipid droplet association was shown to prevent the
production of virions in this work. The localization of our deletion
B bearing NS5A to lipid droplets was therefore of significant
interest. Using a lipid droplet specific fluorescent dye and NS5A
indirect immunofluorescence microscopy we compared the
localization of wild type and deletion B NS5A proteins in the
context of cells electroporated with replication competent full-
length viral genomes. Figure 7 shows the results of this analysis,
with panels showing lipid droplet and NS5A staining, as well as
merged images to examine co-localization. Panels B and C show
close up views of this analysis for wild type and deletion B bearing
genomes, respectively. In the case of both mutant and wild type
NS5A proteins, we see localization of NS5A to lipid droplets. We
were unable to observe any difference in the localization of NS5A
in any of our efforts in this regard, suggesting that deletion B is
functionally quite different than the NS5A mutant that blocks
infectivity release by disrupting localization to lipid droplets [7].
Discussion
The idea of NS5A as a regulator of events in the HCV lifecycle
via phosphorylation by cellular kinases is not a new concept.
Indeed, this idea has been prevalent in the HCV community since
the discovery that NS5A exists in multiple phosphorylation states
[21]. Considerable progress has been made in deciphering the role
of CKIa phosphorylation of NS5A in RNA replication [22]. The
functional significance of CKII phosphorylation of NS5A,
however, has long been an enigma. Our data provides the first
evidence for a function of these events, not in RNA replication, but
in the process of virion assembly.
We have shown that CKII likely phosphorylates serine 457 of
genotype 2a NS5A, and this modification is required for infectious
virus production. Generating an NS5A that is incapable of serving
as a phosphoacceptor (alanine mutation at position 457) does not
alter RNA replication, but blocks the production of infectious
virus. Generating an aspartic acid mutation at position 457 lowers
RNA replication slightly but does not affect infectivity release. This
lack of direct coupling of replication levels and infectivity release is
in agreement with that observed for the JC1 chimeric virus [44], in
which infectivity is increased ten fold with no change in RNA
replication levels. Our first interpretation of this data was that
phosphorylation of serine 457, mimicked by the aspartic acid
mutation, destabilized the replicase leading to release of NS5A and
viral RNA from the replicase for assembly events. This idea is
roughly equivalent to the models of phosphorylation as a regulator
of the replicase first proposed by Evans, et al. [26,44]The case is
clearly not this simple for our mutants, as we see NS5A
participating in later events in assembly, such as association with
lipid droplets even when serine 457 (and surrounding residues) are
deleted. In this regard, our data is quite different than the recently
described NS5A mutants in domain I that block infectious virus
Figure 7. Deletion B does not alter the localization of NS5A to lipid droplets. A). Immunofluorescence microscopy of lipid droplets and
NS5A from wild type J6/JFH-1 (top row) and a J6/JFH-1 virus bearing the deletion B mutation (bottom row). A merged color image of the lipid
droplets and NS5A stained images is also shown (merge). B. A close up of a region of the wild type J6/JFH-1 merged image shown in A. White arrows
indicate lipid droplets coated with NS5A. C. A close up of a region of the deletion B bearing J6/JFH-1 merged image shown in A. Arrows indicate lipid
droplets coated with NS5A.
doi:10.1371/journal.ppat.1000032.g007
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droplets [7]. These mutations are severely impaired in RNA
replication, yet release what appear to be non-infectious virus
particles containing both HCV core and viral RNA. In contrast,
our deletions and single amino acid serine 457 to alanine mutant
in domain III does not alter HCV RNA replication, but blocks the
production of infectious virus, and does not release large amounts
of viral RNA and HCV core. We see no defect in the association of
NS5A with lipid droplets with our deletion B mutant, further
highlighting the difference between domain I and domain III
mutants in NS5A assembly activities. Collectively, these data
suggest our mutants affect a different step in the HCV assembly
pathway than the domain I mutations [7]. Our lack of
understanding of the mechanisms of HCV assembly make it
difficult to speculate exactly what step in assembly our mutations
are affecting. We are clearly manipulating an early step in the
assembly process, as we do not see virus particles inside the cell
secretory pathway, suggesting, in conjunction with the lack of
RNA and core release, that particles are simply not generated.
The data suggests that we are affecting a later stage in assembly
than the domain I mutants, as we see clear evidence of lipid
droplet association of NS5A in the context of our mutant. What
this later step of assembly might be is unknown. Perhaps it involves
NS5A making productive interactions with the structural proteins
at the lipid droplet, NS5A moving and releasing viral RNA, NS5A
functioning to package viral RNA, or NS5A directly being
packaged into virions as a minor component of the infectious
virion. Unfortunately, our understanding of the properties of
NS5A is still in its infancy, making directly addressing these issues
difficult at the present time.
Although our genetic manipulations of NS5A suggest serine 457
is phosphorylated by CKII, and we can show phosphorylation of
fusion protein substrates corresponding to this region of NS5A, we
have not shown direct modification of this residue by this kinase in
the context of an authentic virus infection. Indeed, only two sites of
NS5A phosphorylation have been mapped to date, and not in the
context of authentic RNA replication, despite intense efforts in this
regard over the past 15 years [47,48]. This is, at least in part, due
to the large number of potential acceptor sites in NS5A and the
unusual repetitive amino acid usage of potential acceptor sites in
several regions of NS5A. Our efforts in attempting to identify
serine 457 as a phosphoacceptor from NS5A isolated from infected
cells by immunoprecipitation and mass spectrometry have not
been successful due to poor coverage of the domain III region of
NS5A in our spectra (data not shown). Based on the lack of
evidence in the literature of documented NS5A phosphorylation
sites, and our lack of understanding of what the differences in
phosphorylation that generate the different phosphoforms of
NS5A, it will likely be some time before the complete complement
of NS5A phosphorylation sites are known. Even understanding
whether this site is a component of the hypo or hyperpho-
sphorylated form of NS5A is not a simple task. Serine 457 lies in a
region of NS5A domain III that is believed to primarily contain
sites of hypophosphorylation based on alanine scanning mutagen-
esis of potential acceptor sites in domain III, although this
particular residue position has never been evaluated by mutagen-
esis in the context of the 2a NS5A sequence [11]. Our Western
blot data suggests serine 457 may either be a hyperphosphoryla-
tion site, or a residue that when phosphorylated, promotes
hyperphosphorylation of NS5A. The later seems more likely, as
aspartic acid mutations at serine 457 have normal levels of
hyperphosphorylation, despite being incompetent as an acceptor
site. The work of Miyanari, et al. shows that the lipid droplet
associated form of NS5A, a requirement for virus assembly, is
enriched for hyperphosphorylated NS5A relative to what is seen in
viruses lacking the core protein, suggesting hyperphosphorylation
might be important in assembly. This is, at least in broad terms,
supported by the observation that hyperphosphorylated NS5A
destabilizes the replicase. Nonetheless, in vitro phosphorylation
reactions of NS5A with recombinant CKII only generate the
hypophosphorylated form of NS5A, even in conditions of excess
CKII [25]. At least for CKI phosphorylation of NS5A in vitro,
several acceptor sites require activation by pre-phosphorylation of
upstream sites before they are modified, suggesting that in vitro
reactions probably do not fully represent what occurs in vivo [25].
Although we have shown serine 457 is an important residue in
infectious virus production, it may be that this residue merely
‘activates’ other phosphoacceptor sites, as has been observed for
CKIa phopshorylation. This concept fits well with our observa-
tions of altered levels of hyperphosphorylation with our mutants.
Although the cell culture infectious genotype 2a strain clearly
possesses an insertion relative to other HCV genotypes (Figure 1A),
it is unlikely that this insertion is directly related to the ability to
generate infectious virus. Clearly, isolates of genotype 1a are
infectious in cell culture, but lack this insertion [34]. Indeed, we
can delete this region without disrupting infectious virus
production. The conservation of a CKII site around residue 457
seems to be a more likely candidate for an important conserved
feature, with other defects preventing the production of infectious
virus in cell culture for other genotypes. In this regard, it is worth
noting that the web based NetPhosK 1.0 server [41] can predict
CKII sites in all 35 HCV genotype reference sequences in the Los
Alamos HCV database [49] that involve direct serine 457
modification. A recent paper looking at the sequence of patient
isolated HCV RNA for genotypes 1a, 1b and 3 identified a
number of potential CKII sites in NS5A, including sites very close
to the location of serine 457 in genotype 2a, however the majority
of the sites predicted have residues corresponding to serine 457 as
sites of modification by another enzyme that generate a CKII
recognition site just upstream of this position [50]. This analysis
was based on the site motif described by Pinna [51], in which most
CK2 sites typically have a serine or threonine, followed by an
acidic residue at the n+3 position. This work did not take into
account, as mentioned by Pinna, that whenever the negatively
charged determinant is absent at position n+3, it is invariably
present at position n+1 and vice-versa, leading to some variability
in CK2 sites [51]. The majority of sites we predicted as conserved
across all HCV reference strain had met these rules of the more
conventional n+3, but many were of the less common n+1 variety.
We also were able to predict the sites using an upstream CK2 site
with serine 457 serving as an activator when phosphorylated, as
described by Dal Pero and colleagues [50]. Unfortunately, it will
likely be some time before the intricacies of NS5A phosphoryla-
tion, RNA replication, and now virion assembly, will be fully
understood, thereby addressing the question of what type of CK2
sites are utilized in this region of NS5A. The lack of solid
information on the regulation of CKII further complicates our
understanding of when CKII might be active on NS5A and at
what location in the infected cell (see [52] for review).
The requirement for phosphorylation of a viral non-structural
viral replication protein by a host cell kinase for the production of
infection virus particles, although novel for HCV, has been
described previously for other viruses. Bluetongue virus (BTV) is
perhaps the closest example of this phenomenon to what we
observe in the case of HCV, despite the great evolutionary
distance between these viruses. The BTV NS2 protein is
phosphorylated by CKII, and this phosphorylation is required
for the assembly of the site of replication virion assembly, termed
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mechanisms of this phenomenon are not fully understood in BTV
biology. Viruses more closely related to HCV, such as the
flaviviruses Dengue (DENV) and West Nile virus (WNV), require a
functional c-Src (or c-Src like) kinase activity for the assembly and
maturation of infectious virus particles at the site of RNA
replication [54,55]. The mechanism of these events is also
unknown, but the relatively close relationship of DENV and
WNV to HCV suggest c-Src and c-Src like activities and CKII
may perform similar regulatory functions in switching between
replication and assembly. It seems that the regulation of switching
between replication and assembly by phosphorylation, or
controlling later stages of assembly and mturation may be a
common, but understudied mechanism in virology.
In summary, we have identified serine 457 of the HCV NS5A
protein as a key determinant for the production of infectious
virions and presented data showing this site is likely a target for
CKII phosphorylation. Phosphorylation of this residue appears to
be an important regulatory step in infectious virus production. Via
genetic and chemical manipulations we have shown that HCV
RNA replication can be uncoupled from infectious virus
production without altering HCV RNA replication efficiency. It
remains to be demonstrated whether these observations are valid
in the context of an infected liver, but at least in cell culture these
events appear to be a critical step in the virus lifecycle.
Nonetheless, these new genetic and chemical tools, when
combined with recently identified mutants in NS5A that alter
localization to the site of virion assembly, will be of significant
value in further dissection of the mechanisms of HCV RNA
replication and virion biogenesis.
Materials and Methods
Clones, Cells, and Antibodies
The construction of the J6/JFH-1, J6/JFH-1 pol-, H77/JFH-1,
and pSGR-JFH-1replicon have been described previously [31]. We
generated these clones using a J6/JFH-1 chimeric virus backbone
generated in house by oligo based gene synthesis. Deletions and
mutations in NS5A were generated using the QuikChange
mutagenesis system following the manufacturer’s instructions. All
constructs, subclones, and mutants were confirmed by DNA
sequence analysis. The pCMVSport6 vectors encoding the human
CKII a and a9 cDNA sequences were obtained from Dr. Michael
Conkright. Huh-7.5 (human hepatoma) cells were obtained from an
original seed stock of this clone and cultured as described previously
[35]. The anti-human CKII a (A300-197A) and CKII a9 (A300-
199A) purified rabbit polyclonal antibodies were obtained Bethyl
Labs. The anti human b-actin mouse monoclonal loading control
antibody (A-5441) was obtained from Sigma Aldrich. The anti-
NS5A 9E10 antibody has been described previously [31].
Secondary antibody horseradish peroxidase conjugates were
obtained from Pierce Biotechnology.
Electroporation of Viral RNAs
Viral RNAs were generated and purified as described previously
[31]. For electroporation, subconfluent monolayer cultures of
Huh-7.5 cells were trypsinized, washed twice in ice cold RNase
free phosphate buffered saline (Cambrex, Bio-Whitaker), and
resuspended at a concentration of 1.25610
7 cells/ml in ice cold
RNase free PBS. A 400 ml aliquot of cells was then mixed with
1 mg of HCV viral RNA and electroporated using a BTX
ECM830 square wavelength electroporator in a 2 mm gap
cuvette. Electroporation conditions were 5 pulses of 920 volts for
99 microseconds with 1.1 second intervals. Following a ten minute
recovery time, cells were removed form the cuvette and diluted
into 13.6 milliliters of DMEM +10% FBS.
Virus Replication and Infectivity by
Immunohistochemistry and Virus Titering
Monitoring virus replication and infectivity by IHC was
performed as described previously [31], with minor modifications.
Briefly, Huh-7.5 cells electroporated with HCV RNA were plated
and incubated for 48 hours. Cell supernatants were then harvested
and filtered through a 0.2 micron filter and stored for infection of
naı ¨ve cells. The cell monolayers were then washed twice in PBS
and fixed in methanol. For infection studies, naı ¨ve cells were
inoculated with the filtered supernatant. Following a six hour
incubation, the inoculum was replaced with fresh DMEM +10%
FBS and cells were incubated for a total of 48 hours. Cells were
then washed and fixed in methanol. Fixed cells were then probed
for NS5A expression using the 9E10 monoclonal antibody and
procedure described previously [31]. The limiting dilution virus
titering assay was performed as described previously [31].
HCV RNA quantitation
For measuring HCV RNA levels in cell lysates following various
experimental treatments, cells were washed twice in PBS and
RNAs were then purified using the Qiagen RNeasy kit using the
manufacturer’s instructions. For measuring HCV RNA levels in
cell culture supernatants, electroporated cells were plated for
24 hours, washed 3 times in PBS, trypsinized/split 1:2, and plated
for an additional 48 hours. Supernatants were then harvested and
RNA extracted using the Qiagen Qia Amp UltraSens Virus kit
using the manufacturer’s instructions. Extracted, purified RNAs
were quantified by UV absorbance and 100 nanograms of total
RNA was used for real time reverse transriptase PCR. All real time
PCR experiments were performed using a Roche lightcycler 480
using HCV specific primers and probe as described previously
[39]. Values are normalized using the human GAPDH endoge-
nous control primer set (Applied Biosystems, # 4326317E).
Intracellular virus release
Huh-7.5 cells were electroporated with the appropriate HCV
RNAs as described herein. 5610
5 electroporated cells were plated
in a 35 mm dish in DMEM +10% FBS and incubated at 37uC for
2 days. Culture media was then removed, the cells were washed
twice in PBS and trypsinzed. The cells were then collected by
centrifugation at 5,0006g for 5 minutes and resuspended in 2 ml
of DMEM +10% FBS and lysed by four rounds of freezing and
thawing. Cell lysates were then centrifuged at 5,0006 g for
5 minutes, filtered through a 0.2 micron filter and buffered with
the addition of HEPES pH 7.4 to a final concentration of 20 mM.
DMAT treatment
2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole
(DMAT) was purchased from EMD Biosciences and dissolved in
sterile dimethyl suffixed (DMSO). Following the electroporation of
J6/JFH-1 or J6/JFH1 DEED mutant RNA, cells were plated and
incubated at 37uC for four hours. Cell culture media was then
replaced with media supplemented with DMAT in DMSO or
DMSO only. Cells were then incubated for 48 hours. Cell
supernatants were then collected, filtered through a 0.2 micron
filter, and titered for the presence of infectious virions. Cell lysates
were collected for determination of HCV RNA levels. Cell
viability was determined using the Celltiter-Glo assay on DMAT
treated or control DMSO only treated cells. For experiments using
the control compound, 2-aminopurine (2-AP), cells were treated
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infected with a high titer stock of J6/JFH-1 virus. In some
experiments, 2-AP was left in the culture medium at 1 mM
(maximum concentration without toxicity) for the course of the
experiment. Output virus was harvested and titered by limiting
dilution. To determine the effects of DMAT inhibition of NS2
stability, cells electroporated with JC1 viral RNA were treated
with DMAT for 48 hours, lysed and probed for NS2 using the
6H6 monoclonal antibody. b-actin was used as a loading control
for these experiments.
CKII siRNA experiments
Pre-annealed, validated Silencer siRNA mixtures targeting
human CKII a (siRNA # 1337) and a9 (siRNA # 183) and an
irrelevant siRNA (siRNA # 4611) were purchased from Ambion.
Electroporation of siRNAs was performed as described previously
[56], with minor modifications. One nanomole of RNA duplexes
was electroporated with 2.5610
6 Huh-7.5 cells in 0.4 ml of RNase
free PBS. Electroporation conditions were the same as used for
HCV genomic RNA delivery. Cells were infected 72 hours after
electroporation with a multiplicity of 5 for 6 hours, rinsed with
media, then maintained for 2 days at 37uC. Cell supernatants and
lysates were then harvested for assessment of HCV replication
(infectious particles released and intracellular RNA level) and cell
viability (Celltiter-Glo assay, Promega).
CKII messenger RNA quantitation
Real-time reverse transcriptase PCR analysis of CKII gene
expression was performed using Applied Biosystems pre-designed
Taqman assays and total cellular RNA prepared as described for
HCV specific real time PCR analysis. CKII a was assayed using
assay number Hs00601957_m1. CKII a9 was assayed using assay
Hs00176505_m1. Values were normalized for RNA level using
the expression of human GAPDH (Applied Biosystems, #
4326317E).
CKII Over-expression Studies
Huh-7.5 cells were transfected with pCMV-Sport6 vectors
expressing CKII a, a9, or an empty vector control using Fugene 6
transfection reagent. Following a 24 hour incubation, cells were
infected with J6/JFH-1 virus for 4 hours, washed, and incubated a
further 48 hours, at which point supernatants were collected for
virus titering. The levels of CKII a and a9 in these experiments
were demonstrated by Western blotting of cell lysates using CKII
specific anti-sera as described above. b-actin was used as a loading
control in these experiments.
HCV Core Protein ELISA
For core protein release assays, Huh-7.5 cells were electropo-
rated with J6/JFH-1, J6/JFH-1 deletion B, or J6/JFH-1 pol-
RNA. Supernatants were harvested at 24 hours post transfection
and HCV core protein was measured using the Ortho Diagnostics
Trak-C HCV core ELISA kit following the manufacturer’s
instructions.
GST Fusion Protein Production and Phosphorylation
To generate GST fusion proteins of the deletion B region of
NS5A, complementary 59 phosphorylated oligos were generated
coding for amino acid 449–465 of the JFH-1 NS5A protein with
either a serine or an alanine at position 457. The oligos we
designed such that when annealed they generated appropiate ends
for direct cloning into a pGEX6p1 vector previously digested with
BamHI and EcoRI. The resulting pGEX6p1 vectors encoded
deletion B fused to the C-terminus of GST. After DNA sequence
analysis to confirm the clones were correct, we transferred these
vectors to E.coli strain BL21 and induced the production of the
fusion protein with IPTG. Briefly, 1 liter LB broth cultures of
BL21 cells with the appropriate fusion protein encoding vector
were grow at 37uC until an OD600 of 0.6 was reached. Cells were
then induced by the addition of 1 mM b-2-D-isopropyl-thio-
galactoside and grown for an additional 4 hours at 37uC. Cells
were then pelleted, resuspended in 20 ml of cold buffer A (25 mM
Tris-HCl pH 8.0, 25 mM NaCl, and 20% glycerol) and lysed by
three passes through an Avestin air emulsifier. Lysates were
clarified by centrifugation at 25,0006g for 20 minutes at 4uC, and
the soluble fractions were loaded onto a 5 ml HiTrap GST FF
column equilibrated in buffer A. After extensive washing of the
column to remove unbound material, the fusion proteins were
eluted with buffer A supplemented with 10 mM reduced
glutathione. The reduced glutathione was then removed by
desalting the proteins into buffer A using a HiPrep 26/10
desalting column. The purity of proteins was assessed by SDS-
PAGE and concentrations were determined by Bio-Rad protein
assay. For in vitro phosphorylation experiments 25 ml reactions
were prepared containing 2 mM of each fusion protein, 100 mM
unlabeled rATP, 5 mCi of c-
32P-rATP, in 16CKII kinase reaction
buffer (New England Biolabs). Phosphorylation was initiated by
the addition of 500 units of recombinant human CKII (New
England Biolabs), and reactions were subsequently incubated at
30uC for 30 minutes. After incubation, 100 ml of PBS was added
to the reaction, followed by 50 ml of a 50% slurry of glutathione
4B agarose (GE Healthcare) equilibrated in PBS. Proteins were
allowed to bind to the agarose beads for 10 minutes at 4uC, the
centrifuged at top speed in a microfuge, and the unincorporated
label (supernatant) was removed. This pelleting and washing step
was repeated 4 times. After washing, pellets were resuspended in
100 ml of PBS and transferred to a scintillation vial with 10 ml of
aqueous scintillation cocktail and counted using a Beckman liquid
scintillation counter.
NS5A and Lipid Droplet Visualization
To visualize lipid droplets and NS5A, cells were electroporated
with 1 mg of the appropriate HC RNA, plated in glass slide micro-
chambers, incubated 48 hours, fixed by a 20 minute incubation in
4% paraformaldehyde and probed with 5 mg/ml BODIPY 493/
503 (Invitrogen/Molecular Probes) for lipid droplet staining and a
1:15,000 dilution of the 9E10 monoclonal anti-NS5A antibody
and an Alexa 568 secondary antibody (Invitrogen/Molecular
Probes). Slides were then mounted in Vectashield (Vector Labs)
soft mounting medium and visualized.
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